Intra-Cellular Therapies - ITCI Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $90.17
  • Forecasted Upside: 38.00%
  • Number of Analysts: 10
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 9 Buy Ratings
  • 0 Strong Buy Ratings
$65.34
▼ -1.03 (-1.55%)

This chart shows the closing price for ITCI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Intra-Cellular Therapies Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ITCI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ITCI

Analyst Price Target is $90.17
▲ +38.00% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Intra-Cellular Therapies in the last 3 months. The average price target is $90.17, with a high forecast of $120.00 and a low forecast of $62.00. The average price target represents a 38.00% upside from the last price of $65.34.

This chart shows the closing price for ITCI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 10 investment analysts is to moderate buy stock in Intra-Cellular Therapies. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/1/2022
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/1/2023
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/30/2023
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/28/2023
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/26/2023
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/24/2024
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/24/2024
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/24/2024

Latest Recommendations

  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/7/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$90.00Low
4/24/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$120.00Low
4/23/2024Canaccord Genuity GroupBoost TargetBuy ➝ Buy$100.00 ➝ $107.00Low
4/22/2024Needham & Company LLCBoost TargetBuy ➝ Buy$82.00 ➝ $90.00Low
4/22/2024MizuhoBoost TargetBuy ➝ Buy$82.00 ➝ $96.00Low
4/17/2024TD CowenBoost TargetBuy ➝ Buy$80.00 ➝ $90.00Low
4/17/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$83.00 ➝ $103.00Low
4/17/2024Bank of AmericaBoost TargetBuy ➝ Buy$82.00 ➝ $91.00Low
4/17/2024The Goldman Sachs GroupBoost TargetNeutral ➝ Neutral$67.00 ➝ $77.00N/A
4/16/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$82.00Low
4/5/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$82.00Low
4/3/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$86.00Low
2/23/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$86.00Low
2/23/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$101.00Low
2/23/2024Canaccord Genuity GroupLower TargetBuy ➝ Buy$101.00 ➝ $100.00Low
2/23/2024Needham & Company LLCBoost TargetBuy ➝ Buy$72.00 ➝ $82.00Low
2/16/2024MizuhoBoost TargetBuy ➝ Buy$76.00 ➝ $82.00Low
1/31/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$86.00Low
1/18/2024The Goldman Sachs GroupBoost TargetNeutral ➝ Neutral$58.00 ➝ $64.00Low
1/3/2024Robert W. BairdInitiated CoverageOutperform$83.00Low
1/2/2024Bank of AmericaBoost TargetBuy ➝ Buy$74.00 ➝ $82.00Low
12/14/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$101.00Low
12/11/2023TD CowenInitiated CoverageOutperform$75.00Low
11/3/2023Royal Bank of CanadaLower TargetOutperform ➝ Outperform$77.00 ➝ $76.00Low
11/3/2023Cantor FitzgeraldBoost TargetOverweight ➝ Overweight$98.00 ➝ $101.00Low
11/3/2023Needham & Company LLCBoost TargetBuy ➝ Buy$71.00 ➝ $72.00N/A
8/22/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$98.00Low
8/4/2023Morgan StanleyReiterated RatingOverweight ➝ Overweight$80.00Low
8/4/2023Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$78.00 ➝ $79.00Low
8/4/2023Cantor FitzgeraldBoost Target$90.00 ➝ $98.00Low
8/3/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$73.00Low
7/6/2023Needham & Company LLCBoost Target$70.00 ➝ $73.00Low
6/30/2023UBS GroupBoost Target$74.00 ➝ $80.00Low
6/5/2023JPMorgan Chase & Co.Boost Target$58.00 ➝ $62.00Low
5/8/2023MizuhoBoost Target$74.00 ➝ $76.00Low
5/5/2023Cantor FitzgeraldBoost Target$87.00 ➝ $90.00Low
4/20/2023Morgan StanleyInitiated CoverageOverweight$80.00Low
4/18/2023Needham & Company LLCReiterated RatingBuy$66.00Low
3/29/2023Needham & Company LLCReiterated RatingBuy$66.00Low
3/29/2023Canaccord Genuity GroupBoost TargetBuy$93.00 ➝ $98.00Low
3/29/2023Cantor FitzgeraldBoost TargetOverweight$83.00 ➝ $87.00Low
3/29/2023Bank of AmericaBoost TargetBuy$62.00 ➝ $63.00Low
3/29/2023MizuhoBoost TargetBuy$66.00 ➝ $74.00Low
3/9/2023JPMorgan Chase & Co.Lower TargetOverweight$59.00 ➝ $58.00Low
3/3/2023MizuhoLower Target$72.00 ➝ $66.00Low
3/2/2023Royal Bank of CanadaLower TargetOutperform$75.00 ➝ $71.00Low
3/1/2023Needham & Company LLCReiterated RatingBuy$70.00Low
2/10/2023Needham & Company LLCReiterated RatingBuy$70.00Low
2/1/2023Cantor FitzgeraldReiterated RatingOverweight$83.00Low
11/4/2022Canaccord Genuity GroupBoost Target$90.00 ➝ $93.00Low
10/3/2022MizuhoReiterated RatingBuy$72.00Low
8/22/2022The Goldman Sachs GroupDowngradeBuy ➝ Neutral$64.00 ➝ $49.00Low
8/11/2022MizuhoLower TargetBuy$75.00 ➝ $72.00Low
8/10/2022Needham & Company LLCBoost TargetBuy$65.00 ➝ $67.00Low
7/6/2022MizuhoInitiated CoverageBuy$74.00N/A
6/13/2022UBS GroupInitiated CoverageBuy$75.00Low
4/22/2022Piper SandlerInitiated CoverageNeutral$59.00High
4/21/2022SVB LeerinkBoost TargetOutperform$65.00 ➝ $70.00High
3/2/2022SVB LeerinkBoost TargetOutperform$50.00 ➝ $65.00Low
2/25/2022Needham & Company LLCBoost TargetBuy$59.00 ➝ $65.00Medium
2/16/2022The Goldman Sachs GroupInitiated CoverageBuy$64.00Low
12/21/2021Royal Bank of CanadaBoost TargetOutperform$50.00 ➝ $55.00High
12/20/2021Needham & Company LLCBoost TargetBuy$55.00 ➝ $59.00High
12/20/2021SVB LeerinkBoost TargetOutperform$45.00 ➝ $50.00High
11/10/2021Royal Bank of CanadaBoost TargetOutperform$48.00 ➝ $50.00High
10/27/2021BTIG ResearchReiterated RatingBuy$40.00High
10/24/2021SVB LeerinkReiterated RatingBuyLow
10/21/2021Needham & Company LLCInitiated CoverageBuy$56.00High
10/19/2021Royal Bank of CanadaBoost TargetOutperform$44.00 ➝ $48.00High
9/22/2021Needham & Company LLCInitiated CoverageBuy$55.00Medium
9/20/2021Jefferies Financial GroupBoost TargetBuy$55.00 ➝ $70.00High
12/29/2020Cantor FitzgeraldBoost TargetOverweight$53.00 ➝ $54.00N/A
12/15/2020Bank of AmericaInitiated CoverageBuy$40.00High
12/10/2020The Goldman Sachs GroupInitiated CoverageBuy$38.00High
11/2/2020Royal Bank of CanadaLower TargetOutperform$43.00 ➝ $36.00High
11/2/2020BTIG ResearchLower TargetBuy$80.00 ➝ $40.00High
9/10/2020Royal Bank of CanadaBoost Target$33.00 ➝ $43.00High
9/9/2020BTIG ResearchBoost Target$68.00 ➝ $80.00Low
9/9/2020JMP SecuritiesBoost TargetOutperform$47.00 ➝ $54.00N/A
3/3/2020BTIG ResearchLower TargetBuy$73.00 ➝ $68.00Medium
2/19/2020Evercore ISIInitiated CoverageOutperformMedium
2/18/2020Cantor FitzgeraldReiterated RatingOverweight$43.00 ➝ $47.00High
1/31/2020JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$19.00 ➝ $26.00Low
12/23/2019BTIG ResearchBoost TargetBuy$34.00 ➝ $73.00High
9/10/2019SVB LeerinkReiterated RatingBuyLow
9/10/2019JMP SecuritiesSet TargetBuy$21.00N/A
9/10/2019Cantor FitzgeraldSet TargetBuy$27.00N/A
8/12/2019Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$16.00 ➝ $16.00Low
8/8/2019JMP SecuritiesLower TargetMarket Outperform$24.00 ➝ $21.00High
8/7/2019Royal Bank of CanadaSet TargetBuy$26.00Low
7/8/2019CowenReiterated RatingBuy$28.00High
(Data available from 5/24/2019 forward)

News Sentiment Rating

0.87 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/27/2023
  • 6 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/26/2023
  • 10 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
12/26/2023
  • 11 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/25/2024
  • 19 very positive mentions
  • 22 positive mentions
  • 3 negative mentions
  • 2 very negative mentions
2/24/2024
  • 18 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/25/2024
  • 15 very positive mentions
  • 20 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
4/24/2024
  • 18 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
5/24/2024

Current Sentiment

  • 18 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Intra-Cellular Therapies logo
Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.
Read More

Today's Range

Now: $65.34
Low: $64.88
High: $66.48

50 Day Range

MA: $68.88
Low: $64.76
High: $79.84

52 Week Range

Now: $65.34
Low: $45.50
High: $84.89

Volume

152,971 shs

Average Volume

912,240 shs

Market Capitalization

$6.90 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.01

Frequently Asked Questions

What sell-side analysts currently cover shares of Intra-Cellular Therapies?

The following Wall Street research analysts have issued stock ratings on Intra-Cellular Therapies in the last twelve months: Bank of America Co., Canaccord Genuity Group Inc., Cantor Fitzgerald, JPMorgan Chase & Co., Mizuho, Morgan Stanley, Needham & Company LLC, Robert W. Baird, Royal Bank of Canada, StockNews.com, TD Cowen, The Goldman Sachs Group, Inc., and UBS Group AG.
View the latest analyst ratings for ITCI.

What is the current price target for Intra-Cellular Therapies?

12 Wall Street analysts have set twelve-month price targets for Intra-Cellular Therapies in the last year. Their average twelve-month price target is $90.17, suggesting a possible upside of 38.0%. Cantor Fitzgerald has the highest price target set, predicting ITCI will reach $120.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $62.00 for Intra-Cellular Therapies in the next year.
View the latest price targets for ITCI.

What is the current consensus analyst rating for Intra-Cellular Therapies?

Intra-Cellular Therapies currently has 1 hold rating and 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for ITCI.

What other companies compete with Intra-Cellular Therapies?

How do I contact Intra-Cellular Therapies' investor relations team?

Intra-Cellular Therapies' physical mailing address is 430 EAST 29TH STREET, NEW YORK NY, 10016. The biopharmaceutical company's listed phone number is (464) 440-9333 and its investor relations email address is [email protected]. The official website for Intra-Cellular Therapies is www.intracellulartherapies.com. Learn More about contacing Intra-Cellular Therapies investor relations.